Phase III study of cisplatin plus S-1 (CS) compared with docetaxel and cisplatin plus S-1 (DCS) as first-line therapy for advanced gastric cancer(JCOG1013, GC_CS/DCS_P3 ADOPT) - Adding docetaxel to cisplatin plus tegafur-gimeracil-oteracil for advanced gastric cancer(JCOG1013,GC_CS/DCS_P3 ADOPT)

Japan Clinical Oncology Group (JCOG)0 个研究点目标入组 741 人开始时间: 2012年4月3日最近更新: 2023年10月17日

适应症

试验速览

See the datails via "URL releasing results" above. Also the details can be seen in the JCOG website: http://www.jcog.jp/en/trials/index.html

•1) Multiple primary cancers with disease-free period less than 5 years, except carcinoma in situ or intra mucosal disease cured by local therapy 2) Active infection 3) Fever more than 38c 4) Pregnant, unwilling to practice contraception during the study, or lactating female 5) Uncontrolled psychiatry disease 6) Chronic daily treatment with oral or intravenous corticosteroids 7) Uncontrolled diabetes mellitus or chronic daily treatment with insulin 8) Unstable angina, or past history of myocardial infarction in 6 months 9) Evidence of any other serious disease; renal failure, hepatic failure, interstitial pneumonitis or lung fibrosis 10) Active bleeding 11) Massive pleural effusion, more than half of thoracic space at least one-side

发起方

Japan Clinical Oncology Group (JCOG)